Blog

Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati/X

Dec 15, 2023, 06:27

Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared on X/Twitter:

“Check out our poster on display today at the American Society of Hematology (ASH23).
-High-risk cytogenetics (HG-CTG) loses prognostic impact with inotuzumab ozogamicin (InO) and blinatumomab (Blina) added to frontline HyperCVAD chemotherapy in newly diagnosed patients with Philadelphia negative B-cell Acute Lymphoblastic Leukemia.
-Further analysis underway.”

Source: Jayastu Senapati/X

Acute Lymphoblastic Leukemia American Society of Hematology ASH23 blinatumomab cancer High-risk cytogenetics (HG-CTG) HyperCVAD inotuzumab ozogamicin Jayastu Senapati MD Anderson Cancer Center OncoDaily Oncology

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage